TLR7 and breast carcinoma: Intratumoral delivery of cytosine–phosphate–guanine oligodeoxynucleotides (CpG ODN), a TLR9 agonist, or of R848, a TLR7/8 agonist, showed tumoricidal activity in melanoma and breast cancer mouse models [155,156].